Cyriel Y Ponsioen1, Urban Arnelo2, Annika Bergquist2, Erik A Rauws3, Vemund Paulsen4, Paolo Cantú5, Ilaria Parzanese5, Elisabeth M De Vries3, Kim N van Munster3, Karouk Said2, Olivier Chazouillères6, Benoit Desaint6, Astrid Kemgang6, Martti Färkkilä7, Schalk Van der Merwe8, Werner Van Steenbergen8, Hanns-Ulrich Marschall9, Per-Ove Stotzer9, Douglas Thorburn10, Stephen P Pereira10, Lars Aabakken4. 1. Department of Gastroenterology & Hepatology, Amsterdam UMC, University of Amsterdam, the Netherlands. Electronic address: c.y.ponsioen@amc.uva.nl. 2. Department of Gastroenterology & Hepatology, Karolinska University Hospital, Huddinge, Karolinska Institutet, Sweden. 3. Department of Gastroenterology & Hepatology, Amsterdam UMC, University of Amsterdam, the Netherlands. 4. Department of Gastroenterology & Hepatology, Rikshospitalet, Oslo, Norway. 5. Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. 6. Department of Hepatology, Hôpital Saint Antoine, Paris, France. 7. Department of Gastroenterology & Hepatology, Helsinki University Hospital, Helsinki, Finland. 8. Department of Gastroenterology & Hepatology, Universiteitsziekenhuis Leuven, Leuven, Belgium. 9. Department of Hepatology, Sahlgrenska University, Gothenburg, Sweden. 10. Institute of Liver & Digestive Health, University College London and Sheila Sherlock Liver Centre, Royal Free Hospital, London, United Kingdom.
Abstract
BACKGROUND & AIMS: Dominant strictures occur in approximately 50% of patients with primary sclerosing cholangitis (PSC). Short-term stents have been reported to produce longer resolution of dominant strictures than single-balloon dilatation. We performed a prospective study to compare the efficacy and safety of balloon dilatation vs short-term stents in patients with non-end-stage PSC. METHODS: We performed an open-label trial of patients with PSC undergoing therapeutic endoscopic retrograde cholangiopancreatography (ERCP) at 9 tertiary-care centers in Europe, from July 2011 through April 2016. Patients found to have a dominant stricture during ERCP were randomly assigned to groups that underwent balloon dilatation (n = 31) or stent placement for a maximum of 2 weeks (n = 34); patients were followed for 24 months. The primary outcome was the cumulative recurrence-free patency of the primary dominant strictures. RESULTS: Study recruitment was terminated after a planned interim analysis because of futility and differences in treatment-related serious adverse events (SAEs) between groups. The cumulative recurrence-free rate did not differ significantly between groups (0.34 for the stent group and 0.30 for the balloon dilatation group at 24 months; P = 1.0). Most patients in both groups had reductions in symptoms at 3 months after the procedure. There were 17 treatment-related SAEs: post-ERCP pancreatitis in 9 patients and bacterial cholangitis in 4 patients. SAEs occurred in 15 patients in the stent group (45%) and in only 2 patients in the balloon dilatation group (6.7%) (odds ratio, 11.7; 95% confidence interval, 2.4-57.2; P = .001). CONCLUSIONS: In a multicenter randomized trial of patients with PSC and a dominant stricture, short-term stents were not superior to balloon dilatation and were associated with a significantly higher occurrence of treatment-related SAEs. Balloon dilatation should be the initial treatment of choice for dominant strictures in patients with PSC. This may be particularly relevant to patients with an intact papilla. ClinicalTrials.gov no. NCT01398917.
RCT Entities:
BACKGROUND & AIMS: Dominant strictures occur in approximately 50% of patients with primary sclerosing cholangitis (PSC). Short-term stents have been reported to produce longer resolution of dominant strictures than single-balloon dilatation. We performed a prospective study to compare the efficacy and safety of balloon dilatation vs short-term stents in patients with non-end-stage PSC. METHODS: We performed an open-label trial of patients with PSC undergoing therapeutic endoscopic retrograde cholangiopancreatography (ERCP) at 9 tertiary-care centers in Europe, from July 2011 through April 2016. Patients found to have a dominant stricture during ERCP were randomly assigned to groups that underwent balloon dilatation (n = 31) or stent placement for a maximum of 2 weeks (n = 34); patients were followed for 24 months. The primary outcome was the cumulative recurrence-free patency of the primary dominant strictures. RESULTS: Study recruitment was terminated after a planned interim analysis because of futility and differences in treatment-related serious adverse events (SAEs) between groups. The cumulative recurrence-free rate did not differ significantly between groups (0.34 for the stent group and 0.30 for the balloon dilatation group at 24 months; P = 1.0). Most patients in both groups had reductions in symptoms at 3 months after the procedure. There were 17 treatment-related SAEs: post-ERCP pancreatitis in 9 patients and bacterial cholangitis in 4 patients. SAEs occurred in 15 patients in the stent group (45%) and in only 2 patients in the balloon dilatation group (6.7%) (odds ratio, 11.7; 95% confidence interval, 2.4-57.2; P = .001). CONCLUSIONS: In a multicenter randomized trial of patients with PSC and a dominant stricture, short-term stents were not superior to balloon dilatation and were associated with a significantly higher occurrence of treatment-related SAEs. Balloon dilatation should be the initial treatment of choice for dominant strictures in patients with PSC. This may be particularly relevant to patients with an intact papilla. ClinicalTrials.gov no. NCT01398917.
Authors: Vilja Koskensalo; Andrea Tenca; Marianne Udd; Outi Lindström; Mia Rainio; Kalle Jokelainen; Leena Kylänpää; Martti Färkkilä Journal: United European Gastroenterol J Date: 2020-03-08 Impact factor: 4.623
Authors: Amaninder S Dhaliwal; Yassin Naga; Daryl Ramai; Syed M Saghir; Sarav G Daid; Banreet Dhindsa; Andrew Ofosu; Pushpak Taunk Journal: Ann Gastroenterol Date: 2022-03-25
Authors: Moritz Peiseler; David Reiners; Hans O Pinnschmidt; Marcial Sebode; Franziska Jung; Johannes Hartl; Roman Zenouzi; Hanno Ehlken; Stefan Groth; Guido Schachschal; Thomas Rösch; Christina Weiler-Normann; Ansgar W Lohse; Christoph Schramm Journal: PLoS One Date: 2018-08-20 Impact factor: 3.240
Authors: Christian Rupp; Theresa Hippchen; Thomas Bruckner; Petra Klöters-Plachky; Anja Schaible; Ronald Koschny; Adolf Stiehl; Daniel Nils Gotthardt; Peter Sauer Journal: Gut Date: 2019-03-25 Impact factor: 23.059